Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

1. Selected dates can't be greater than February 2026. 2. From date can't be greater than To date. 1. Selected dates can't be greater than February 2026. 2. From date can't be greater than To date. 1.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...